XENCOR INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
XENCOR INC. - More news...
XENCOR INC. - More news...
- Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
- Xencor Reports First Quarter 2021 Financial Results
- Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases
- Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021
- Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
- Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021
- Xencor to Present at the Barclays Global Healthcare Conference
- Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
- Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
- Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
- Xencor to Present at Upcoming Investor Conferences
- Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer
- Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
- Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
- Xencor to Present at Upcoming Investor Conferences
- Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
- Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting
- Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
- Xencor Reports Third Quarter 2020 Financial Results
- Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
- Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020
- Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting
- Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
- Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
- Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
- Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates
- Xencor to Present at Upcoming Investor Conferences
- Xencor Reports Second Quarter 2020 Financial Results
- Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
- Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020
